NICE - Endorsed Technology Appraisals 2013/2014

It is important to note that the advice contained within the guidance does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.

Technology Appraisals Endorsement Process

The following technology appraisals were endorsed during 2013-14 using the process that came into effect on 18 December 2013.  Other technology appraisals endorsed during 2013-14 under the previous process are detailed further down the page. Information on technology appraisals endorsed in previous years can be found on the homepage

Fully Endorsed

March 2014

February 2014

December 2013

The following technology appraisals were endorsed during 2013-14 using the process that came into effect on 28 September 2011:

Fully Endorsed 

November 2013

October 2013

September 2013

  • NICE TA 295 - Everolimus in combination with an aromatase inhibitor for the treatment of HER2 negative, oestrogen receptor positive locally advanced or metastatic breast cancer after prior endocrine therapy
    • This guidance has been updated and replaced by TA421 - Everolimus with exemestane for treating advanced breast cancer after endocrine therapy, which was endorsed by the DoH in January 2017.

August 2013

July 2013

June 2013

May 2013

April 2013

Endorsed with Caveats 

None 

Not Endorsed as Applicable to Northern Ireland 

None

 

Back to top